# Genmab (GMAB) — News

GMAB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gmab/news

## Recent headlines

- [Genmab: UBS raises target price to DKK 3100 from DKK 2700](https://www.ainvest.com/news/genmab-ubs-raises-target-price-dkk-3100-dkk-2700-2610) — AInvest Wire, Oct 14, 2026
- [Genmab - Darzalex Q3 2026 net sales USD 2.53 bln in U.S., USD 1.71 bln rest of world](https://www.ainvest.com/news/genmab-darzalex-q3-2026-net-sales-usd-2-53-bln-usd-1-71-bln-rest-world-2610) — AInvest Wire, Oct 13, 2026
  Genmab A/S (Nasdaq: GMAB) reported third-quarter 2026 net sales of DARZALEX® (daratumumab) in the United States of USD 2.53 billion, with USD 1.71 billion in sales from the rest of the world, according to data provided by Johnson & Johnson. This represents a decline in U.S. sales compared to the…
- [Genmab A/S: Barclays raises target price to DKK 3100 from DKK 2900](https://www.ainvest.com/news/genmab-barclays-raises-target-price-dkk-3100-dkk-2900-2610) — AInvest Wire, Oct 9, 2026
- [Genmab: Deutsche Bank raises target price to DKK 3000 from DKK 2750](https://www.ainvest.com/news/genmab-deutsche-bank-raises-target-price-dkk-3000-dkk-2750-2610) — AInvest Wire, Oct 9, 2026
  Deutsche Bank has raised its price target for Genmab A/S to DKK 3,000 from DKK 2,750, while maintaining its "buy" rating . The adjustment follows recent positive developments in Genmab’s pipeline, including the first Phase 3 data for its lymphoma treatment, Epkinly, in the EPCORE-DLBCL2 trial,…
- [Genmab: BofA global research raises price objective to DKK 2850 from DKK 2500](https://www.ainvest.com/news/genmab-bofa-global-research-raises-price-objective-dkk-2850-dkk-2500-2610) — AInvest Wire, Oct 8, 2026
  Genmab shares rose over 8% on October 8, 2026, following the company’s second-quarter results and an updated 2026 outlook. The Danish biotech firm reported first-half revenue of $2.05 billion, a 25% increase compared to $1.64 billion in the same period of 2025, driven by higher royalties from…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).